IMVT-1402 Misses Primary Endpoint in Cutaneous Lupus Proof-of-Concept Trial

Immunovant announced topline results from a proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in patients with cutaneous lupus erythematosus (CLE), reporting that the investigational therapy did not achieve statistical significance on the study’s primary efficacy endpoint. The company subsequently announced that it does not plan to continue development of IMVT-1402 in CLE.¹

The randomized, double-blind, placebo-controlled global study (NCT06980805) enrolled 57 adults with CLE. During the first 12-week treatment period, participants were randomized to receive IMVT-1402 or placebo. The primary endpoint evaluated percent change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12.¹

Although the primary endpoint was not met, Immunovant reported numerical trends favoring IMVT-1402 across multiple study endpoints. According to the company, patients who achieved deeper reductions in immunoglobulin G (IgG) from baseline were also more likely to experience improved clinical responses.

However, Immunovant stated that the results, considered alongside the competitive treatment landscape in CLE, did not meet its internal threshold for continued development in the indication.

Safety Findings Remain Consistent With Earlier Studies

IMVT-1402 demonstrated a favorable safety and tolerability profile in the CLE trial, consistent with findings from previous clinical studies, according to Immunovant.¹

IMVT-1402 is an investigational fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). FcRn inhibition is designed to reduce circulating IgG, including potentially pathogenic IgG autoantibodies implicated in several autoimmune diseases.

Earlier phase 1 testing of IMVT-1402 demonstrated dose-dependent reductions in IgG. In a multiple-ascending-dose cohort evaluating 600-mg subcutaneous dosing, Immunovant previously reported deep IgG reductions without meaningful changes in serum albumin or low-density lipoprotein cholesterol.²

Results Follow Earlier Clinical Signals in CLE

The proof-of-concept results contrast with encouraging observations previously reported from individual patients with CLE treated with IMVT-1402.

In an earlier case study reported by Immunovant, a 57-year-old woman with subacute CLE, alopecia, and a baseline CLASI-A score of 36 received IMVT-1402 600 mg weekly for 12 weeks. Her CLASI-A score decreased by more than 60%, reaching 13 at week 12, alongside an approximately 78% reduction in total IgG from baseline. A second patient experienced a greater than 50% improvement in CLASI-A, with the score decreasing from 18 at screening to 8 by week 12.³

Those early observations contributed to interest in FcRn inhibition as a potential approach to CLE. However, the randomized proof-of-concept study did not confirm a statistically significant benefit on its prespecified primary endpoint.

“On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care,” Eric Venker, MD, PharmD, chief executive officer of Immunovant, said in the announcement. “Their contributions advance our understanding of FcRn inhibition in autoimmune disease and will inform our work going forward.”¹

Development Continues in Other Autoimmune Diseases

The CLE results are not expected to alter Immunovant’s other clinical development timelines for IMVT-1402. The company continues to evaluate the FcRn inhibitor across several autoimmune diseases, including Graves disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjögren disease.¹

Earlier in 2026, Immunovant reported preliminary efficacy findings from the open-label portion of its difficult-to-treat rheumatoid arthritis program. At week 16, ACR20, ACR50, and ACR70 response rates were 72.7%, 54.5%, and 35.8%, respectively, among evaluable patients. Further development of IMVT-1402 in that and the company’s other ongoing indications remains on track.⁴

The CLE findings therefore narrow the clinical development program for IMVT-1402 but also provide additional information about the relationship between the depth of IgG reduction and clinical response. Additional data will be needed to determine the relevance of that pharmacodynamic relationship across other autoimmune indications.

References

1. Immunovant. Immunovant announces topline results from proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus. Published September 23, 2026.
2. Immunovant. Immunovant announces positive IMVT-1402 initial 600 mg MAD results that confirm best-in-class potential. Published November 28, 2023.
3. Immunovant. Annual Report for the fiscal year ended March 31, 2026. Published May 20, 2026.
4. Immunovant. Immunovant provides corporate updates and reports financial results for the fourth quarter and fiscal year ended March 31, 2026. Published May 20, 2026.